Biochemistry of Collagens, Laminins, and Elastin: Structure, Function and Biomarkers, Third Edition provides current data on key structural proteins (collagens, laminins, and elastin), reviews on how these molecules affect pathologies, and information on how selected modifications of these proteins can result in altered signaling properties of the original extracellular matrix (ECM). Further, it discusses the novel concept that an increasing number of components of the extracellular matrix harbor cryptic signaling functions with ties to endocrine function, and how this knowledge may be used to modulate various pathologies, including fibrotic disease.
This new edition has been expanded and revised to incorporate recent research advances. Several new chapters explore a range of chronic diseases in which the ECM and collagens, laminin and elastin are central players in disease modulation, including new chapters on lung, skin and intestinal disease, as well as cancers. The new edition also considers emerging analytical technologies that can detect biomarkers of ECM degradation, with discussion of protein quantification and detecting aging of collagens.
Table of Contents
1. Type I Collagen2. Type II Collagen3. Type III Collagen4. Type IV Collagen5. Type V Collagen6. Type VI Collagen7. Type VII Collagen8. Type VIII Collagen9. Type IX Collagen10. Type X Collagen11. Type XI Collagen12. Type XII Collagen13. Type XIII Collagen14. Type XIV Collagen15. Type XV Collagen16. Type XVI Collagen17. Type XVII Collagen18. Type XVIII Collagen19. Type XIX Collagen20. Type XX Collagen21. Type XXI Collagen22. Type XXII Collagen23. Type XXIII Collagen24. Type XXIV25. Type XXV Collagen26. Type XXVI Collagen27. Type XXVII Collagen28. Type XXVIII Collagen29. Laminins30. Elastin31. The collagen Chaperones32. Collagen diseases33. The Signals of the extracellular matrix34. The roles of collagens in cancer and fibrosis35. Use of extracellular matrix biomarkers in clinical research36. Common confounders when evaluating noninvasive protein biomarkers37. ECM and endotypes38. The new collagen family39. Collagen receptors40. Dermatitis and skin diseases41. The basements membrane quantification of respiratory diseases42. The fibrosis and collagens of IBD43. ECM biomarkers in population-based studies (PERF)44. The collagen biomarkers of chronic diseases45. One protein a 1000 neoepitopes understanding of the epitope46. Aging the most important collagen neo-epitope?47. FibronectinAuthors
Morten Karsdal CEO, Nordic Bioscience A/S, Herlev, Denmark.Morten Karsdal has been CEO of Nordic Bioscience A/S since June 2010.
Since 2002, Morten Karsdal has focused his research on the discovery and development of novel biochemical markers. This has resulted in the development of more than 15 ELISA assays for detecting biomarkers that have been used for research in the fields of fibrosis, osteoporosis and osteoarthritis. One of these assays has been 510(k) approved by the Food and Drug Administration (FDA) in the USA.
